What is CHPA’s position on the Combat Meth Act, a federal initiative which restricts the sales and placement of over-the-counter medicines containing pseudoephedrine?
CHPA is pleased to lend its support to The Combat Meth Act, a federal initiative aimed at addressing the methamphetamine problem in this country. This legislation, signed into law March 2006, includes sales and product placement restrictions on OTC medicines containing pseudoephedrine (PSE) to prevent the diversion of PSE to methamphetamine. The Combat Meth Act became fully effective September 30, 2006. Recognizing that sales and product placement restrictions alone will not stop the meth problem, CHPA supports tough, comprehensive measures to attack this problem at every level of its manufacture and use, and feels that efforts to restrict precursors combined with substantial funding to states to fight meth use and trafficking will make a dramatic impact in the manufacture of methamphetamine in the United States. In addition to the sales and placement restrictions, CHPA was pleased that The Combat Meth Act included $99 million each year for five years beginning in 2006 for state and lo
